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The need for more 
investment in 
tuberculosis research 
We welcome the insightful Article 
on ﬁ nancing for tuberculosis control 
by Katherine Floyd and colleagues 
(August, p e105)1 from the Global TB 
programme at WHO. The ﬁ nding that 
many countries, including the BRICS 
countries (Brazil, Russia, India, China, 
and South Africa), are becoming 
increasingly self-suﬃ  cient in funding 
tuberculosis control is truly a success 
story, and one that the investigators 
should be applauded for documenting. 
However, tuberculosis control also 
requires research into new preventive 
measures, diagnostic approaches, and 
drugs, which were beyond the scope 
of Floyd and colleagues’ study. Recent 
analyses by the Treatment Action 
Group,2 Research Investments in 
Global Health (RESIN),3 and G-FINDER4 
report a relative underinvestment for 
tuberculosis compared with other 
high-burden infectious diseases.
Research investments are poorly 
documented, particularly among the 
BRICS countries, which is detrimental 
to the task of finding innovative 
solutions to address today’s global 
health problems. With rising multidrug 
resistance and the continued search for 
a new tuberculosis vaccine, stimulating 
research through increased investment 
warrants prompt attention.
WHO is currently reviewing the 
feasibility of establishing a Global 
Observatory for Research and 
Development.5,6 We strongly support 
this eﬀ ort. However, pharmaceutical 
companies need to be more open 
with their research portfolios, which 
could translate into more effective 
tuberculosis control in the near future. 
Financing for tuberculosis care 
and control is improving. However, 
interpreting the latest estimates 
without data for research investments 
could lead us to a false sense of 
security, particularly with the growing 
threats of multidrug-resistant 
tuberculosis, HIV co-infection, and an 
unpredictable economic climate. 
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